What exactly changed in the March 10, 2026 BNTX analyst rating updates?

On March 10, 2026 Morgan Stanley maintained an Overweight rating and a Buy rating on BioNTech SE. StreetInsider also published a separate note that BofA reduced its price target to $128. The updates kept sentiment positive but lowered some near-term price expectations.

How should investors interpret a maintained Buy with a lower price target?

A maintained Buy means the analyst still sees net upside versus peers. A lower price target narrows expected gains. Combine the **BNTX analyst rating** with pipeline, cash flow, and risk factors before making decisions.

Does the March 10 coverage change long-term outlook for BioNTech SE?

The March 10 notes show differing near-term views, but they do not by themselves change long-term fundamentals. The **BNTX analyst rating** remains mostly constructive, while target revisions reflect nearer-term caution.

Where can I find the source analyst notes for these ratings?

StreetInsider published the March 10 items. See the Morgan Stanley reiteration [here](https://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Reiterates+Overweight+Rating+on+BioNTech+%28BNTX%29%3A+%22timing+of+announcement+likely+driving+weakness+in+stock%22/26137899.html) and the BofA price‑t

Analyst Ratings

Morgan Stanley Maintains Overweight Buy on BioNTech SE (BNTX) March 10, 2026

ByDanny Kontos March 11, 2026

Morgan Stanley on March 10, 2026 maintained its Overweight and Buy calls on BioNTech SE (BNTX), keeping pressure on near-term expectations. This update anchors the latest discussion around the BNTX analyst rating and follows headline news that BofA trimmed a price target to $128. Investors should note both the maintained positive stance from Morgan Stanley and the lower target from BofA when weighing risk versus reward.